Clinical Trial Update: A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating orelabrutinib for primary progressive multiple sclerosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Zenas BioPharma (USA), LLC | Conditions: Multiple Sclerosis (MS) Primary Progressive | Phase 3 | Status: RECRUITING